SCHEMBL5041100

SCHEMBL5041100

CCOC(C(=O)NCc1ccc(C(=N)NC(=O)OCc2ccccc2)cc1)c1c(F)cc(Oc2ccc(OC)cc2)cc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MASP2 O00187 4/20 0.43
F10 P00742 1/20 0.41
CTSD P07339 1/20 0.40
KMT2A Q03164 1/20 0.39
NPC1 O15118 3/20 0.38
ALDH1A1 P00352 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
ALOX12 P18054 1/20 0.38
CYP2C19 P33261 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
KLKB1 P03952 1/20 0.38
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38
ATM Q13315 1/20 0.38
RAB9A P51151 1/20 0.38
CTSL P07711 1/20 0.37
CTSS P25774 1/20 0.37
CTSK P43235 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5043460 0.94 MASP2 (0.42) MASP2F10CTSDNPC1ALDH1A1
SCHEMBL5045462 0.93 F10 (0.44) MASP2F10CTSDALDH1A1CYP1A2
SCHEMBL5043052 0.91 MASP2 (0.42) MASP2F10KLKB1PPARGPPARA
SCHEMBL5037329 0.89 MASP2 (0.47) MASP2F10ALDH1A1KLKB1LMNA
SCHEMBL6068687 0.87 MAPK14 (0.43) MASP2F10KLKB1PPARGPPARA
SCHEMBL5043478 0.87 MASP2 (0.47) MASP2CTSDKMT2ANPC1ALDH1A1
SCHEMBL6068661 0.87 MASP2 (0.40) MASP2F10KMT2ANPC1ALDH1A1
SCHEMBL5041098 0.84 PLAU (0.39) F10CTSDKMT2ANPC1ALDH1A1
SCHEMBL5041095 0.84 PLAU (0.39) F10CTSDKMT2ANPC1ALDH1A1
SCHEMBL5041773 0.83 MASP2 (0.45) MASP2F10ALDH1A1KLKB1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567498-B1 MANDELIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-23 EP disclosed
US-7129238-B2 Mandelic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-31 US disclosed
EP-1567498-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-08-31 EP disclosed
US-20040122057-A1 Novel mandelic acid derivatives HOFFMANN-LA ROCHE INC. 2004-06-24 US disclosed
WO-2004048335-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122057-A1 Novel mandelic acid derivatives F7, F11, F9 MASP2 370/4885F10 8/4885CTSD 1491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.